Mammary Cell News Volume 13.12 | Apr 1 2021

May 12, 2022

MCN 13.12 | Apr 1 2021

Mammary Cell News by STEMCELL Technologies

Vol. 13.12 – 1 April, 2021

TOP STORY

Landscapes of Cellular Phenotypic Diversity in Breast Cancer Xenografts and Their Impact on Drug Response

A single-cell breast cancer mass cytometry panel was optimized to identify cell phenotypes and their oncogenic signaling states in a biobank of patient-derived tumour xenograft models representing the diversity of human breast cancer.
[Nature Communications]

Full Article

Explore scientific events this April with the Science Events Calendar.

PUBLICATIONSRanked by the impact factor of the journal

The Oncogene AAMDC Links PI3K-AKT-mTOR Signaling with Metabolic Reprograming in Estrogen Receptor-Positive Breast Cancer

Researchers uncovered that Adipogenesis associated Mth938 domain containing (AAMDC) regulated the expression of several metabolic enzymes involved in the one-carbon folate and methionine cycles, and lipid metabolism.
[Nature Communications]

Full Article

Breast Cancer Dependence on MCL-1 Is Due to Its Canonical Anti-Apoptotic Function

Scientists investigated the role of MCL-1 in clinically relevant breast cancer models and addressed whether the canonical role of MCL-1 in apoptosis, which could be targeted using BH3-mimetic drugs, was the major function for MCL-1 in breast cancer.
[Cell Death & Differentiation]

Full Article

Liver X Receptor Alpha Drives Chemoresistance in Response to Side-Chain Hydroxycholesterols in Triple Negative Breast Cancer

The authors showed that LXR ligands confered chemotherapy resistance in TNBC cell lines and xenografts, and that LXRalpha was necessary and sufficient to mediate this resistance.
[Oncogene]

Full Article

The Deubiquitinating Enzyme USP15 Stabilizes ERα and Promotes Breast Cancer Progression

By exploring the regulatory mechanisms of estrogen receptor α (ERα) at levels of post-translational modifications, investigators identified the deubiquitinase USP15 as a novel protector for preventing ERα degradation and a critical driver for breast cancer progression.
[Cell Death & Disease]

Full Article

Co-Dependency for MET and FGFR1 in Basal Triple-Negative Breast Cancers

Researchers utilized an established Met-dependent transgenic mouse model of TNBC, human cell lines and patient-derived xenografts to investigate the role of MET in TNBC tumorigenesis.
[npj Breast Cancer]

Full Article

The Human Intermediate Prolactin Receptor Is a Mammary Proto-Oncogene

An analogous truncated mouse prolactin receptor (mPRLr) was found to be oncogenic when co-expressed with wild-type mPRLr. The authors determined if a similar transforming event occurs with the hPRLr in human breast epithelial cells.
[npj Breast Cancer]

Full Article

Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases

Researchers showed that β3 integrin induction by the bone microenvironment promotes resistance to chemotherapy through an altered metabolic response that can be defused by combination with αvβ3-targeted mTORC1 inhibitor nanotherapy.
[Molecular Cancer Therapeutics]

Abstract

RANK Signaling Increases after Anti-HER2 Therapy Contributing to the Emergence of Resistance in HER2-Positive Breast Cancer

Scientists showed that RANK bound to HER2 in breast cancer cells and that enhanced RANK pathway activation altered HER2 phosphorylation status.
[Breast Cancer Research]

Full Article

Anti-Estrogenic and Anti-Aromatase Activities of Citrus Peels Major Compounds in Breast Cancer

The authors investigated the antitumor potential of the most potent compounds in citrus peels on breast cancer by exploring their anti-estrogenic and anti-aromatase activities.
[Scientific Reports]

Full Article

Differential Reprogramming of Breast Cancer Subtypes in 3D Cultures and Implications for Sensitivity to Targeted Therapy

Researchers systematically compared the transcriptomes of these different culture conditions by RNAseq of 14 breast cancer cell lines cultured in both 2D and 3D conditions.
[Scientific Reports]

Full Article

MiR-142-3p Targets HMGA2 and Suppresses Breast Cancer Malignanc

Investigators demonstrated that the miRNA miR-142-3p directly targeted the 3′ untranslated region of HMGA2, which encoded an onco-embryonic protein that was overexpressed in most cancers, including breast cancer.
[Life Sciences]

Abstract

Survey results on the insights and hurdles of CRISPR genome editing.

REVIEWS

3D Bioprinting of Engineered Breast Cancer Constructs for Personalized and Targeted Cancer Therapy

The authors emphasized on the prospective future applications of 3D bioprinted cancer models for rapid and accurate drug screening in breast cancer.
[Journal of Controlled Release]

Abstract Graphical Abstract

INDUSTRY AND POLICY NEWS

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck announced that the FDA has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Application seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant treatment after surgery.
[Merck (BusinessWire, Inc.)]

Press Release

FEATURED EVENT

Landscapes of Cellular Phenotypic Diversity in Breast Cancer Xenografts and Their Impact on Drug Response

The Oncogene AAMDC Links PI3K-AKT-mTOR Signaling with Metabolic Reprograming in Estrogen Receptor-Positive Breast Cancer

Breast Cancer Dependence on MCL-1 Is Due to Its Canonical Anti-Apoptotic Function

Liver X Receptor Alpha Drives Chemoresistance in Response to Side-Chain Hydroxycholesterols in Triple Negative Breast Cancer

The Deubiquitinating Enzyme USP15 Stabilizes ERα and Promotes Breast Cancer Progression

Co-Dependency for MET and FGFR1 in Basal Triple-Negative Breast Cancers

The Human Intermediate Prolactin Receptor Is a Mammary Proto-Oncogene

Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases

RANK Signaling Increases after Anti-HER2 Therapy Contributing to the Emergence of Resistance in HER2-Positive Breast Cancer

Anti-Estrogenic and Anti-Aromatase Activities of Citrus Peels Major Compounds in Breast Cancer

Differential Reprogramming of Breast Cancer Subtypes in 3D Cultures and Implications for Sensitivity to Targeted Therapy

MiR-142-3p Targets HMGA2 and Suppresses Breast Cancer Malignanc

3D Bioprinting of Engineered Breast Cancer Constructs for Personalized and Targeted Cancer Therapy

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Metabolism in Health and Disease

> See All Events

Postdoctoral Fellowship – Breast Cancer Immunology and Immunotherapy

Medicinal Chemist – Muscle-Wasting, Neurodegeneration, and Oncology

Research Instructor – Pathology, Anatomy and Cell Biology

Director – Ginny L. Clements Breast Cancer Research Institute

Research Coordinator – Breast Oncology

> See All Jobs